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Running Title: Biophysical and Structural Characterization of Nuclear Hormone Receptors 1 
All cellular organisms require the ability to integrate and respond to intra and extra-
cellular signals. In eukaryotic organisms, complex signaling machineries have been developed 
for this purpose. The Nuclear Hormone Receptor (NR) superfamily of proteins is one such 
mechanism. This family encompasses a large number of structurally and functionally similar 
proteins that regulate a wide variety of physiological processes, such as toxin clearance, growth 
and development, and homeostasis, through activation of transcription of target genes. This 
thesis will deal primarily with biophysical, biochemical, and structural investigations into the 
Nuclear Receptor family of proteins, with the goal of furthering our understanding of the 
structures and functions of these proteins.  
The discovery of hormones and steroids in the early 20th century catalyzed the 
investigations that would eventually lead to the discovery of Nuclear Receptors. Hormones and 
steroids were first analyzed for the large-scale effects that could be observed in organisms upon 
their addition; a seminal study involved attributing early amphibian metamorphosis to the 
addition of mammalian thyroid extracts. Further investigations revealed significant effects 
potentiated by other hormone and steroid molecules, including cortisone and estrogen. The 
biological significance of steroid and hormone molecules led to a massive effort to organically 
synthesize these molecules in the lab, which led to the famous race between Woodward and 
Robinson to achieve a total synthesis of Cholesterol. These successes furthered the 
pharmacological interest in the function of hormones and steroids, and by 1961 Jensen had 
radioactively tracked the hormone oestradiol-17β to the nucleus, in complex with a protein. This 
soon led to a new model for the action of hormones and steroids, whereby the function of the 
ligand was to interact with and thereby activate a receptor protein. Improvements in technology 
that spurred the molecular biology revolution also led to the cloning of the Glucocorticoid and 
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Thyroid Hormone Receptor in the lab of Ron Evans, and the Estrogen Receptor in the labs of 
Pierre Chambon and Geoffrey Greene in the mid 1980’s, which led to a rapid increase in the 
understanding of NR structure and function. Since these seminal experiments, a great many NR 
receptors have been recombinantly purified and examined structurally and functionally, both 
individually and in various complexes with their physiological partners and ligands. Current 
work focuses on ever larger complexes with full-length receptors and their interacting partners to 
more comprehensively understand their physiological functions.  
Though many questions remain, a great deal has been uncovered about the structure of 
NRs. It is now known that NRs are characteristically modular proteins with several domains. 
Most receptors contain six domains: a highly variable N-terminal domain containing an 
Activation Function 1 (AF-1) domain, a well-conserved zinc-finger DNA-binding Domain 
(DBD), a hinge region, a Ligand Binding Domain (LBD), and an Activation Function 2 (AF-2).  
 
Fig 1.1: General structural organization of nuclear receptors. Source: 
http://upload.wikimedia.org/wikipedia/commons/3/3e/Nuclear_Receptor_Structure.png 
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The structures of the individual DBDs and LBDs have been studied intensively by x-ray 
crystallography and biochemical assays, though larger fragments and full-length studies of 
nuclear receptors have been limited by the difficulty of recombinant purification and structural 
characterization. Indeed, only recently have DBD-LBD complexes been successfully analyzed 
by crystallography, scattering, or cryo-EM. These analyses have revealed a general paradigm for 
the function of NRs: ligand activation by binding in the LBD causes dissociation of NRs from 
their co-repressor complexes, and subsequent translocation (if necessary) to their DNA promoter 
sequences as monomers, dimers or heterodimers, upon which the receptors bind coactivator 
molecules to initiate the assembly of the transcription machinery. The dimerization interface, 
which is usually composed of approximately three helices from each receptor subunit, mediates 
allosteric communication between the dimer subunits. The mechanism of coactivator binding is 
fairly well understood in individual cases. In general, ligand binding to the ligand-binding cavity 
induces a conformational change that pulls Helix 12 from a flexible conformation extending 
from the receptor surface to a static conformation lying along the receptor surface. This 
conformational change dissociates corepressor complexes and creates a coactivator interaction 
surface that consists of a hydrophobic groove with “charge clamp” residues to bind to specific 
residues in cognate coactivator proteins. The LBDs also contain the dimerization interface in 
most cases, whereby homodimerization or heterodimerization may occur.  
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Fig 1.2: Diagram of helices in the DBD and LBD of a Retinoid X Receptor : Retinoic Acid Receptor heterodimer. 
The coactivator-interaction surface near H12 and the dimerization interface near H10 are clearly shown. Source: 
http://www.nature.com/nrd/journal/v6/n10/fig_tab/nrd2398_F1.html  
The structure of the LBD, therefore, determines specificity for ligand, coactivator, and other NR 
interactions, and this structure is therefore relatively variable among the different members of the 
NR superfamily. The DBD is by comparison a more conserved subunit, and is most important 
for its zinc-finger DNA recognition function. The DBD connects to the LBD via a short, flexible 
hinge domain whose functional properties remain unclear, despite being evidently significant. 
Most NRs also contain a variably-size N-terminal domain with an AF-1. These domains are very 
weakly conserved throughout the superfamily, and their high degree of flexibility has precluded 
extensive study. While it is understood that this N-terminal domain is important in regulating 
transcription, mechanisms to explain its function are not yet available.  
 A detailed atomic view of both the LBD and DBD is necessary to understand much of 
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modern NR research. Many NR LBDs have now been crystallized, and all reveal a globular 
structure consisting of approximately 12 α-helices. These helices form a set of three antiparallel 
sheets, the interior of which contains the ligand-binding pocket. These ligand binding pockets 
determine their specificity primarily through hydrophobic interactions, though hydrogen bonding 
interactions and specific residue interactions are often critical in determining the orientation and 
affinity for the precise ligand required.  
 
Fig 1.3: Glucocorticoid receptor with dexamethasone bound in the ligand binding pocket. Several charge clamps are 
indicated by yellow lines. Source:http://upload.wikimedia.org/wikipedia/commons/f/f0/Glucocorticoid_receptor.png 
 
The AF-2 domain consists largely of Helix 12, though other helices are also involved. Upon 
binding of agonist ligand, Helix 12 rearranges to form a coactivator interaction surface. 
Coactivators with helical LXXLL sequences are able to bind to these surfaces primarily through 
hydrophobic interactions, with “charge clamp” interactions at each end of the helix mediated 
usually by glutamate and lysine residues on the NR. When bound to antagonist ligand or 
unliganded, most receptors either cannot form the coactivator interaction surface or have a 
corepressor outcompeting the coactivator for the surface. Therefore, ligand binding is a critical 
mediator of NR activity.  
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Fig 1.4: Conformation change associated with the binding of ligands and its physiological impact. 
Source:http://upload.wikimedia.org/wikipedia/commons/thumb/d/d4/NR_mechanism.png/480px-
NR_mechanism.png 
 
The DBD is a highly conserved subunit that consists of two zinc-finger structures. In 
each, a zinc atom is coordinated by four cysteine molecules. Two α-helices also contribute to 
DNA-binding specificity and overall protein stability. The DBD has also been observed to be a 
potent allosteric communicator to other parts of the NR, though precise mechanisms for 
allosteric communication, especially involving the hinge region between LBD and DBD, remain 
unclear. Finally, the DBD can in certain cases contribute a dimerization interface.  
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Fig 1.5: DBDs of an Estrogen receptor dimer on DNA, showing a dimerization interface in the DBD. 
Source: http://www.ks.uiuc.edu/Research/pro_DNA/ster_horm_rec/dbd/dbd_big.gif 
 
The N-terminal regions beyond the DBD remain poorly understood. Atomic resolution of 
these regions has not yet been achieved, however several biochemical assays have yielded hints 
as to the structure and function of these domains. Several studies have shown these regions to be 
mostly disordered, with little secondary structure. However, it has been seen that these regions 
can adopt secondary structure under a variety of conditions, including DNA binding and 
interaction with other transcription factors. Furthermore, this region contains several 
phosphorylation regions that have been linked to its structural instability. Despite these insights, 
an integrated understanding of the many possible functions of these N-terminal regions is still 
not available. Similarly, the flexible hinge region between the LBD and DBD has also been 
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noted to have several important phosphorylation sites, though the functional mechanisms of the 
hinge remain unclear. 
 
Fig 1.6: Diagram indicating phosphorylation sites of some isoforms of RAR and RXR. The N-terminus 
harbors many phosphorylation sites. Source:http://www.nature.com/nrd/journal/v3/n11/images/nrd1551-i1.jpg 
 
There are many open problems currently being pursued in NR research. Since the 90s the 
field has amassed a great amount of information on the structure and function individual 
subunits, and in some cases multiple subunits such as DBD-LBD complexes. One of the key 
challenges moving forward is to integrate this data into the broader context of full-length 
receptor function and interaction with other members of the transcription machinery. Full-length 
atomic studies of NRs will be critical to understand allosteric communication within the 
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receptors, and structural studies of NRs in complex with their interacting partners in the 
transcription machinery will be necessary to achieve a detailed understanding of transcription in 
general. Recent technological developments, particularly on the front of cryo-electron 
microscopy which can now achieve near-atomic resolution of large (>100kD) complexes, should 
speed progress on this front considerably.  
 
Fig 1.7: Schematic overview of cryo-em as a tool for structural biology. 
Source:http://media.americanlaboratory.com/m/20/Article/154443-fig3.jpg 
 
Ultimately, work in this field will move toward a comprehensive understanding of how NRs 
function within the larger context of transcription regulation, including allosteric mechanisms of 
communication and interactions with transcription machinery.  
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Fig 1.8: Illustration of the many factors involved in the larger transcription initiation machinery. Understanding the 
interplay of all of these factors will be necessary for a comprehensive understanding of NR transcriptional activity. 
Source: http://www.nature.com/nrm/journal/v6/n7/images/nrm1680-f2.jpg 
 
This thesis will now briefly diverge from the biology of NRs to describe in detail two 
biophysical techniques that were essential to the work herein presented. These techniques are 
Small-angle X-Ray Scattering and Analytical Ultracentrifugation. An overview of the history of 
the techniques will be presented, followed by a derivation of the basic physics behind the 
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techniques, concluding with practical considerations for their application to the study of 
biological molecules such as NRs.  
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Physical Review: Small-angle X-ray Scattering 
 Through the course of the 19th century several different kinds of radiation were observed 
and characterized, e.g. the discovery of infrared by Hershel in 1800, the discovery of ultraviolet 
by Ritter in 1801, and the discovery of x-rays by Röntgen in 1895. It was Maxwell’s insights into 
the mathematical description of the electromagnetic field which led to the understanding that 
these forms of radiation are all disturbances in the electromagnetic field, thereby composing the 
electromagnetic spectrum.  
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 The understanding of the electromagnetic spectrum allowed for a wide variety of 
applications by using appropriate wavelength radiation to target specific interactions with matter. 
X-rays were used in their first medical application only months after Röntgen’s discovery, 
utilizing the fact that Calcium in bones strongly absorbs x-rays and therefore makes bones highly 
visible in contrast to other biological matter.  
 As understanding of the nature of x-rays developed, so too did applications. A seminal 
breakthrough was achieved by Paul Ewald and Max von Laue in 1912, when they postulated that 
x-rays should have a wavelength conducive to the study of crystal spacings by diffraction. Von 
Laue experimented with this idea by bombarding a crystal of copper sulfate with x-rays and 
recording the resulting diffraction. Von Laue latter developed mathematical relations between 
the scattering angles from the beam to the size and orientation of spacings between unit cells in 
the crystal. This discovery led to a Nobel Prize in physics in 1914, and ushered in a century of 
incredible discovery and development with crystallography.  
 William Bragg and his son together shared the Nobel Prize in Physics in 1915 for their 
work on crystallographic analysis, which included the development of Bragg’s law. These 
developments paved the way for structural determination of molecules by x-ray crystallography. 
Simple organic molecules were first solved in the 1920’s, followed by larger molecules such as 
cholesterol and penicillin. Finally, the age of protein crystallography was ushered in by the 
determination of the structure of myoglobin by Sir John Kendrew in 1958.  
 Though much of the interest and focus of structural studies was on crystallographic 
analysis, there was concurrent development on x-ray techniques that do not required highly 
ordered samples. Guinier and Fournet were pioneers in Small-angle X-ray Scattering (SAXS) 
studies, discovering in the 1930’s that analyzing scattering patterns of molecules in solution 
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yielded information of the sizes, shapes, and internal structures of the molecules. This technique 
remained of interest for samples that were impossible to crystallize, but was difficult to apply 
more generally because of technological limitations. The 1970’s brought a revolution in small-
angle scattering studies, as the development of synchrotrons provided much higher luminosity 
beamlines for researchers. Initially, only a few general parameters about the particles, e.g. radius 
of gyration and volume, were attainable from SAXS curves. The 1990’s brought another 
revolution in SAXS through novel mathematical methods of analysis, which allowed ab initio 
generation of envelope models of the particles to up to 10 angstrom resolution. Currently SAXS 
is experiencing a strong revival of interest due to the powerful new techniques and software 
available for structural analysis of scattering curves coupled with improving beamline 
technology. Though much of the current work in SAXS now focuses on improvements in 
engineering and application, there continue to be advances in the basic theory, as well. 
A succinct overview of x-ray scattering theory will now be presented. A very general 
diagram of a small-angle scattering experiment is provided:  
 
Figure 2.1: Simple diagram of a scattering experiment setup. 
 
A highly collimated plane wave of approximately .1nm x-rays is directed into the sample cell. 
The electron clouds of the atoms in the sample scatter the waves elastically, and the resulting 
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waves are recorded on the detector plate. A beamstop is required to block the direct beam, which 
is many orders of magnitude higher intensity than the scattered radiation.  
 To understand how reconstruction of particle properties can be obtained from a scattering 
pattern, it is necessary to understand how x-rays interact with matter. There are several different 
interactions that incident x-rays may have with matter, and we will classify these as elastic or 
inelastic and coherent or incoherent. For elastic scattering, the incident plane wave causes 
oscillation of electrons according to the electric component of the wave, creating an oscillating 
electric dipole which radiates energy at an equal wavelength in an approximately spherical wave. 
Inelastically, photons of the incident wave may collide with electrons causing a slight but 
appreciable rebounding of the electron, which as a result radiates energy of a slightly different 
wavelength. X-rays may also excite electrons to higher energy levels, which then radiate upon 
following back down to a lower energy state, but do not in general radiate at the same 
wavelength as the incident radiation. X-ray interactions with the nucleus are negligible and will 
not be considered. Finally, a strong enough incident wave may ionize a sample via the 
photoelectric effect, though this is also a negligible effect in most small-angle scattering studies. 
We then characterize these interactions as coherent or incoherent, based on whether or not 
information may be discerned from them. Coherent scattering is Thomson scattering, i.e. 
radiation caused by dipole oscillation of electrons. Incoherent scattering comprises Compton 
scattering, where an electron rebounds off of a photon, Absorption, the Photoelectric effect, 
thermal fluctuations in the sample, and imperfections in sample homogeneity.  
 Finally, before we begin mathematical analysis of the scattering we must make an 
approximation known as the Born approximation. Under this approximation we assume that the 
incident beam is so many orders of magnitude more intense than the weak scattered waves that it 
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is not appreciable changed as it passes through a sample, and therefore all scattering centers in 
the sample are subject to the same beam. This approximation holds for most small-angle 
scattering studies where the particles being studied are very weak scattering sources.  
For a scattering experiment we define a differential scattering cross section as well as a 
solid angle into which the incident radiation through the scattering cross section is scattered. We 
define the scattering angle as the angle between the scattered and incident beam, and the 
scattering length density, b, as a measure of the amplitude of a wave observed per unit incident 
radiation in unit solid angle.   
 
Figure 2.2: Diagram of the mathematical model used to describe scattering. Source: Serdyuk, Zaccai & Zaccai, 
Methods in Molecular Biophysics, Cambridge University Press, 2007. 
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We require a single arbitrary origin to compare wave phases from different scattering sources, 
and so with any arbitrary center we have the following diagram: 
 
Figure 2.3: Modelling the contribution of distance from an arbitrary origin to the phase of the scattered waves. 
Source: Serdyuk, Zaccai & Zaccai, Methods in Molecular Biophysics, Cambridge University Press, 2007. 
 
Where O is the reference point. This allows us to calculate the phase differences between waves. 
From the diagram we can see that: 
𝛿 =
2𝜋(𝑂𝑁 − 𝑂𝑀)
𝜆
 
So the scattered wave relative to O from an atom with scattering amplitude f can be written  
 
𝐴 = 𝑓𝑒𝑥𝑝(𝑖𝛿) 
Or, using wavevector notation and defining Q = k1 – k0 
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Figure 2.4: Wavevector notation, including the definition of scattering angle and q. Source: Serdyuk, Zaccai & 
Zaccai, Methods in Molecular Biophysics, Cambridge University Press, 2007. 
   
So that we have  
𝐴 = 𝑓𝑒𝑥𝑝(𝑖𝑞 ⋅ 𝑟) where 𝑞 =
4𝜋 sin(𝜃)
𝜆
 from the diagram 
Extrapolating to many atoms is simple:  
𝐹(𝑞) =  ∑𝑓𝑗exp⁡(𝑖𝑞 ⋅ 𝑟) 
This begs for a Fourier transform, so we acquiesce 
𝑓(𝑟) =  ∫ 𝐹(𝑞)exp(−𝑖𝑞 ⋅ 𝑟) 𝑑𝑉𝑞 and 𝐹(𝑞) =  𝑓(𝑟)exp∫ (𝑖𝑞 ⋅ 𝑟) 𝑑𝑉𝑟 
This would seemingly give us the scattering amplitude as a function of position, from which we 
could deduce atomic coordinates. However we can only measure |F(q)|2 on the detector.  
For a solution of non-interacting, monodisperse and homogeneous particles we have 
𝐼𝑛(𝑞) =  ∑|𝐹𝑛(𝑞)|
2 
But evidently this is not accurate because the particles in solution are in different orientations. To 
solve this, we approximate that, given enough non-interacting particles, scattering from particles 
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in different orientations is equivalent to scattering from a particle averaged over all orientations. 
Therefore we calculate that:  
< |𝐹(𝑞)|2 >⁡= ⁡∑ ∑ (𝑓𝑗 − 𝜌
0𝜈𝑗)(𝑓𝑘 − 𝜌
0𝜈𝑘)
sin(𝑞𝑟𝑗𝑘)
𝑞𝑟𝑗𝑘
𝑘𝑗   → 
𝐼𝑁(𝑞) = ⁡𝑁∑∑𝑚𝑗𝑚𝑘
𝑘𝑗
sin(𝑞𝑟𝑗𝑘)
𝑞𝑟𝑗𝑘
 
Where the terms 𝑓𝑗 − 𝜌
0𝜈𝑗 represent the contrast amplitude of the j
th atom, and mj is shorthand 
for this term. We can also write this:  
𝐼𝑁(𝑞) = 𝑁∬(𝜌(𝑟𝑗) − 𝜌
0)(𝜌(𝑟𝑘) − 𝜌
0)
sin(𝑞𝑟𝑗𝑘)
𝑞𝑟𝑗𝑘
𝑑𝜈𝑗𝑑𝜈𝑘 
Or, normalized by concentration: 
𝐼𝑁(𝑞)
𝐶
=
𝑁𝐴
𝑀
∑∑𝑚𝑗𝑚𝑘
sin(𝑞𝑟𝑗𝑘)
𝑞𝑟𝑗𝑘
𝑘𝑗
 
Where NA is Avogadro’s number, M is the molecular weight, and C is the concentration.  
This forms the basic foundation for scattering theory.  
Now we will look at mathematical developments that allow for intricate analysis of the 
scattering curve. A major development came from Guinier, who noticed that the low-q part of 
the curve fits well to a Gaussian:  
𝐼(𝑞) = 𝐼(0) exp [−
1
3
𝑅𝑔
2𝑞2] → ln(𝐼(𝑞)) = ln(𝐼(0)) −
1
3
𝑅𝑔
2𝑞2 
This allows for quick and simple determination of I(0) and Rg, as well as data quality validation 
by analyzing the quality of the fit. The Guinier fit, as it is now described, is one of the most 
valuable parameters extracted from a scattering curve, and therefore high quality low-q data is 
very important.  
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Now we turn to using the entire curve. Taking the inverse Fourier transform of I(q) we 
get  
𝑉𝛾(𝑟) = ⁡
1
2𝜋2
∫ 𝑞2𝐼(𝑞)
sin⁡(𝑞𝑟)
𝑞𝑟
𝑑𝑞
∞
0
  where  𝛾(𝑟) =⁡< (𝜌(𝑟𝑗) − 𝜌
0)(𝜌(𝑟𝑘) − 𝜌
0) > 
Where V is the volume of a single particle and 𝛾(𝑟) is the correlation function. From before we 
had 
𝐼𝑁(𝑞) = 𝑁∬(𝜌(𝑟𝑗) − 𝜌
0)(𝜌(𝑟𝑘) − 𝜌
0)
sin(𝑞𝑟𝑗𝑘)
𝑞𝑟𝑗𝑘
𝑑𝜈𝑗𝑑𝜈𝑘 
So now we can Fourier transform 𝑉𝛾(𝑟) to give 
𝐼(𝑞) = 𝑉 ∫4𝜋𝑟2𝛾(𝑟)
sin(𝑞𝑟𝑗𝑘)
𝑞𝑟𝑗𝑘
𝑑𝑟  →  𝐼(𝑞) = ⁡∫ 𝑝(𝑟)
sin(𝑞𝑟𝑗𝑘)
𝑞𝑟𝑗𝑘
𝑑𝑟 
Where p(r) = 4πr2Vγ(r) is the pairwise distribution function, so that now 
𝑝(𝑟) = ⁡
2
𝜋
𝑟2∫ 𝑞2𝐼(𝑞)
∞
0
sin(𝑞𝑟𝑗𝑘)
𝑞𝑟𝑗𝑘
𝑑𝑞 
However it is essential to note that this calculation requires values of I(q) at 0 and ∞, both of 
which must be approximated. Now utilizing this information we can obtain:  
∫ 𝑝(𝑟)𝑟2
𝐷𝑚𝑎𝑥
0
𝑑𝑟 = |∫(𝑝(𝑟) −⁡𝑝0)𝑑𝑣|2 = |∑𝑚𝑗|
2 = 𝐼(0) 
Where Dmax is the maximum dimension of the particle. We also obtain:  
𝑅𝑔
2 =⁡
1
2∫ 𝑝
(𝑟)𝑟2
𝐷𝑚𝑎𝑥
0
𝑑𝑟
∫ 𝑝(𝑟)
𝐷𝑚𝑎𝑥
0
𝑑𝑟
 
And the Porod invariant 
𝐶 =⁡∫ 𝐼(𝑞)𝑞2𝑑𝑞
∞
0
 
And finally the volume 
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𝑉 = ⁡
2𝜋2𝐼(0)
𝐶
 
A good test of data quality is comparing the values obtained from I(0) and Rg obtained 
from the Guinier approximation and integrating the pairwise distribution function. Large 
discrepancies indicate poor data quality. By using the entire curve one can generate envelopes of 
particles based on the pairwise distribution of scattering centers, though the mathematical models 
for ab inito envelope reconstruction are beyond the scope of this review.   
 There are several factors that must be taken into account when preparing for an 
experiment. For high-quality scattering data one should attempt to isolate a sample that is 
monodisperse and homogeneous in both composition and conformation. Methods exist for 
analyzing scattering from heterogeneous systems, but these analyses are more difficult and 
should therefore be avoided if possible. A concentration series should also be used to extrapolate 
out any interparticle effects that arise as a consequence of high concentration of particles. High 
concentration solutions are required for high-q data, but will be most likely to experience inter-
particle effects or aggregation and should therefore be complimented with low-concentration 
samples that can correct for these effects. Analyzing scattering data can be a highly subjective 
process due to the relative lack of information in a scattering curve as compared to, e.g., a crystal 
diffraction data set. Therefore, any additional data that may be obtained on the size, geometry, 
mass, flexibility, and oligomeric state of the particles is very valuable towards constructive 
SAXS analysis. Finally, radiation damage should be considered as a factor in the experiment. 
The effect of radiation damage can be minimized by addition of compounds such as glycerol to 
the buffer, and samples can be analyzed under multiple exposure times to check for radiation 
damage.  
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 In an ideal experiment, a SAXS dataset on a monodisperse, homogeneous sample with a 
broad concentration series range and no interparticle effects will return reasonably accurate 
information on particle size, geometry, radius of gyration, volume, molecular weight, as well as a 
molecular envelope up to a maximum resolution of 1nm. This information, especially when 
coupled with data obtained via other methods e.g. crystallography or binding experiments, can 
yield very valuable structural information on targets that are otherwise hard to analyze 
structurally. SAXS therefore has a promising future in structural biology for analysis of 
multimolecular complexes and disordered systems.  
 
Physical Review: Analytical Ultracentrifugation 
Analytical ultracentrifugation began its history with Theodore Svedberg’s work on gold 
particles in the 1920’s. Svedberg was initially interested in calculating molecular weights of 
colloidal gold particles using a gravitational sedimentation system coupled with an optical 
observation system. Svedberg quickly realized that particles of sufficiently small size would 
require much higher gravitational fields to be able to sediment appreciable, and this would 
require a very powerful centrifuge. This led to the first design of an analytical centrifuge: a 
centrifuge capable of achieving very high gravitational fields in the sample cell coupled to an 
optical system for tracking particle motion. These first designs were largely unsuccessful, 
however, due to poor sample cell design that allowed for convection to complicate the 
hydrodynamics of the system. In 1924 Svedberg was able to design a centrifugal system that 
minimized convection using sector-shaped cells, and it was around this same time that 
Svedberg’s interests shifted from gold colloids to proteins, whose characteristics were still 
almost entirely unknown at the time. In pioneering equilibrium studies on hemoglobin and 
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albumin, Svedberg was able to make some essential observations: the molecular weight of the 
molecules, and the homogeneity of the solutions, which hinted that proteins were large 
macromolecules that could be identically reproduced in the cell. These observations constituted a 
great advance in protein science, and yielded Svedberg the Nobel Prize in 1926. By the end of 
the 1920’s, Svedberg and his colleagues had established analytical ultracentrifugation both in 
theory and instrumentation as an extremely powerful technique for studying biological 
molecules, though widespread use of the technique remained limited due to high cost and 
insufficiently advanced instrumentation.  
 The next great advance in ultracentrifugation came after a massive increase in science 
funding in the United States following the Second World War. In 1950’s a new ultracentrifuge 
was unveiled: the Spinco model E. This centrifuge was much more versatile and user friendly 
than the complicated Svedberg centrifuges, and was rapidly adopted by many labs. These 
centrifuges allowed for a massive increase in the use of centrifugation techniques, and the next 
two decades saw large accumulations of molecular data from ultracentrifugation techniques, 
concurrent with advances in instrumentation, methodology, and theory.  
The 1970’s and the advent of molecular biology techniques such as gel electrophoresis 
and sequencing led to a very rapid decline in interest in ultracentrifugation. The technique 
became expensive and difficult in comparison to simpler methods that sufficiently answered the 
relevant questions of molecular weight and oligomeric status. While advances in theory and data 
collection and acquisition continued, the use of ultracentrifugation as a technique in biochemistry 
was rapidly dying. Two decades of incredible progress in ultracentrifugation were followed by 
two decades of stagnation.  
 In 1992 Beckman introduced a new ultracentrifuge: the XL-A. The XL-A provided two 
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essential improvements: a universal set of hardware and rapid digital data acquisition. This 
centrifuge promised simple and rapid data acquisition and analysis. This led to a sudden 
explosion of interest in analytical ultracentrifugation, contributing to an impressive rebirth of the 
technique as one of the gold standards of biochemical and biophysical analysis. Further advances 
in data analysis continued to improve the accessibility of analytical ultracentrifugation for 
researchers, and the introduction in 1996 of the Beckman XL-I, which allowed for Raleigh 
interference optics in addition to the standard absorption optics, provided ultracentrifugation with 
the versatility required to compete with other techniques to be a valuable tool in the biochemist 
and biophysicist’s arsenal.  
Analytical ultracentrifugation has continued to advance in methodology, theory and 
instrumentation over the years, now boasting a fluorescence optical system in addition to its 
absorbance and interference systems, and programs to collect and analyze data continue to 
improve and become more streamlined. Ultracentrifugation is currently taught in many graduate 
programs as one of the essential tools for biochemical and biophysical studies of molecules, and 
it is expected that ultracentrifugation will continue to be an invaluable tool for many years to 
come.  
Fundamentally, AUC is a simple technique based on the sedimentation of particles in a 
solution when exposed to a centrifugal force. Balancing the forces yields equations that depend 
on the particle mass and geometry and include the particle’s motion, therefore by following the 
motion of a particle (or a boundary) it is possible to deduce molecular parameters of the sample. 
To describe the motion in a sample cell, we use Fick’s diffusion equation with drift included: 
𝐽𝑥 =⁡−𝐷
𝑑𝐶
𝑑𝑥
+ 𝑢𝐶(𝑥) 
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Where D is the diffusion coefficient, u is the angular velocity, C(x) is the concentration as a 
function of x. But the velocity of the particle is dependent on the angular velocity of the cell, the 
position of the particle, and a sedimentation coefficient, in other words  𝑢 = 𝑠𝜔2𝑥 , so: 
𝐽𝑥 =⁡−𝐷
𝑑𝐶
𝑑𝑥
+ 𝑠𝜔2𝑥𝐶(𝑥) 
But we must take into account the geometry of the sample cell. The relevant continuity equation 
is that 
𝑑𝐶
𝑑𝑡
𝑟 = ⁡−
1
𝑟
𝑑𝑟𝐽⁡
𝑑𝑟
𝑡 
So we ultimately obtain the Lamm equation:  
𝑑𝐶
𝑑𝑡
𝑟 = ⁡−
1
𝑟
[
𝑑
𝑑𝑟
(𝜔2𝑟2𝑠𝐶 − 𝐷𝑟
𝑑𝑐
𝑑𝑟
𝑡)] 𝑡 
Analytical solutions of the Lamm equation are not attainable except under very specific 
circumstances that are not particularly useful. However, several numerical methods exist to 
approximate solutions, though these methods will not be described in detail.  
 The sedimentation coefficient computed from the Lamm equation solutions is an 
extremely valuable experimental parameter. To see why, we need to examine how the 
sedimentation coefficient relates to other parameters. We begin by examining the forces on the 
sample, of which there are three: the centrifugal, the buoyant, and the frictional.  
𝐹𝑐 = 𝑚𝜔
2𝑟 
𝐹𝑏 = −𝑚0𝜔
2𝑟 
𝐹𝑑 = −𝑓𝑢 
Where m, m0 are the masses of the sample and solvent displaced, r is the distance from rotor 
center, u is the velocity of the molecule, f is the frictional coefficient, and ω is the angular 
velocity. Equilibrium is obtained upon balancing forces, which gives 
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𝑚𝜔2𝑟(1 − 𝜈𝜌0) = 𝑓𝑢 
Where ν is the partial specific volume of the molecule. On a mole basis 
𝑠 ≔
𝑢
𝜔2𝑟
= 𝑀(1 − 𝜈𝜌0)/𝑁𝐴𝑓 
This is the sedimentation coefficient, in units of seconds, and is one of the main values sought 
after in an AUC experiment.  
Modelling the boundary movement in terms of ρ, η, ν, and f/f0 allows a calculation of the 
C(s) distribution, which sorts molecules in the sample by sedimentation coefficient, from which 
can then be derived a C(M) distribution, which sorts molecules in the sample by molecular 
weight, which is the approach used in SEDFIT. 
An important consideration is that the sedimentation coefficient recorded in buffer must 
be corrected for the standard values expected in water at 20 degrees Celsius, rather than buffered 
solution at lower temperature. 
𝑠20,𝑤 = 𝑠𝑒𝑥𝑝
1 − νρ20,𝑤
1 − νρ𝑒𝑥𝑝
η𝑒𝑥𝑝
η20,𝑤
 
Molecular mass may also be calculated from measurement of the sedimentation and 
diffusion data, though it is prone to errors in measurement of the relevant values. 
𝑠
𝐷
=
𝑀(1 − νρ0)
𝑅𝑇
 
More accurate assessments of mass may be obtained from equilibrium experiments, 
wherein the sample is centrifuged at a high speed for a long enough time to establish equilibrium 
of the forces on the sample. This means that the total flux is 0, which means: 
𝑑𝐶
𝑑𝑡
𝑟 = ⁡−
1
𝑟
[
𝑑
𝑑𝑟
(𝜔2𝑟2𝑠𝐶 − 𝐷𝑟
𝑑𝑐
𝑑𝑟
𝑡)] 𝑡 = 0⁡ → 𝐷(
𝑑𝐶
𝑑𝑟
)𝑡 −⁡𝜔
2𝑟𝐶𝑠 = 0  
Rearranging we get 
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dln(𝐶)
𝑑
𝑟2
2
=
1
𝑟
𝐶
𝑑𝐶
𝑑𝑟
𝜔2𝑠
𝐷
=
𝑀(1 − νρ)𝜔2
𝑅𝑇
 
The concentration distribution falls off exponentially from the meniscus (a) and a point (r): 
𝐶(𝑟) = 𝐶(𝑎) exp [
𝜔2𝑀(1 − νρ)(𝑟2 − 𝑎2)
2𝑅𝑇
] 
Plotting 𝑙𝑛⁡(𝐶(𝑟)) vs 𝑟2/2 yields a straight line for a monodisperse solution, whose slope is 
𝑀(1 − 𝜈𝜌0)𝜔2/𝑅𝑇. For a polydisperse solution, the tangential slope describes gives the average 
molecular mass at that point in the cell.  
 These derivations have provided the relevant equations for basic analytical 
ultracentrifugation experiments running either velocity or equilibrium setups. The programs 
designed to handle the data acquisition and analysis are described elsewhere.  
 There are several practical considerations to take into account when setting up an 
analytical ultracentrifugation experiment. One should first consider which setup, velocity or 
equilibrium, will be most appropriate for the parameters being studied. Velocity experiments 
provide information on particle mass, size, shape, and interactions, while equilibrium provides 
highly accurate data on mass and interactions, and can also be used to test non-ideal behavior of 
molecules. Next, rotor speeds should be chosen to best fit the system being studied. With prior 
knowledge of macromolecular composition, optimal rotor speeds can be approximated based on 
the relevant equations. For example, if either molecular weight or sedimentation coefficient of 
the macromolecules can be estimated, then the optimal rotor speeds for an equilibrium 
experiment can be calculated from the final equation provided above. Finally, buffer solutions 
should be as close to water as feasible in order to minimize error in computing standard values 
for the experimental parameters. Additions such as glycerol, due to its high viscosity, can 
strongly contribute to error in the experiment.  
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Results:  
Agonist-Ligands Mediate the Transcriptional Response of Nuclear Receptor 
Heterodimers through Distinct Stoichiometric Assemblies with Coactivators 
 
ABSTRACT 
The constitutive androstane (CAR) and retinoid X receptors (RXR) are ligand-
mediated transcription factors of the nuclear receptor protein superfamily. Functional 
CAR:RXR heterodimers recruit coactivator proteins, such as the steroid receptor 
coactivator-1 (SRC1). Here, we show that agonist ligands can potentiate transactivation 
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through both coactivator binding sites on CAR:RXR which distinctly bind two SRC1 
molecules. We also observe that SRC1 transitions from a structurally plastic to a compact 
form upon binding CAR:RXR. Using small-angle X-ray scattering (SAXS) we show that the 
CAR(tcp):RXR(9c)/SRC1 complex can encompass two SRC1 molecules compared to the 
CAR(tcp):RXR/SRC1 which binds only a single SRC1. Moreover, sedimentation coefficients 
and molecular weights determined by analytical ultracentrifugation (AUC) confirm the 
SAXS model. Cell-based transcription assays show that disrupting the SRC1 binding site on 
RXR alters the transactivation by CAR:RXR. These data suggest a broader role for RXR 
within heterodimers while offering multiple strategies for the assembly of the transcription 
complex.  
Nuclear hormone receptors (NR) relay cellular signals through distinct multiprotein 
assemblies (1). At the basic level, small-molecule signals produce structural changes within NRs 
and these changes determine the composition of the interacting protein complex. These changes 
are essential for transcriptional activity and appear to be conserved among all ligand-activated 
receptors that have been studied to date. NRs are characteristically modular proteins with distinct 
functional domains (2). At the N-terminus is the DNA binding domain (DBD) which determines 
target-gene selectivity. The ligand-binding domain (LBD) is a multi-functional module that 
contains the ligand-binding pocket, a dimerization interface that associates with the retinoid X 
receptor (RXR) and a C-terminal ligand-dependent transactivation domain (AF2). Multiple 
biochemical and structural studies on nuclear receptors have demonstrated that ligand binding 
results in the specific conformational changes that are associated with a transcriptionally active 
state (3). In this active state, the conformation of the AF2 domains typically rearrange along the 
receptor surface, thereby creating a new docking site for transcriptional coactivator proteins (4). 
Since both receptors within NR heterodimers can bind small-molecule agonist ligands, in the 
simplest model for transactivation, agonist binding to either receptor can generate comparable 
transcriptional levels of downstream genes. Furthermore, this model would predicate that the 
presence of agonists to both receptors at once would yield proportionately higher levels of 
transcription. Such model systems are exemplified by the CAR:RXR (Figure 1A), PPARα:RXR 
and LXR:RXR heterodimers (5). Yet, there are NR heterodimers that exhibit transcriptional 
responses that are distinct from this model (5,6). For instance, transactivation by RAR:RXR, 
VDR:RXR and TR:RXR only occurs in the presence of the RAR, VDR and TR agonists, and when 
used in combination with the RXR agonist, transactivation levels are either enhanced, unaffected 
or are repressed, respectively (5,7). Through structural and biophysical studies, the mechanism of 
transactivation has been recognized to occur through conformational changes that restrict 
recruitment to a single coactivator protein to RAR:RXR (8) or decrease T3 agonist binding-affinity 
to TR:RXR (7).  
CAR is most abundantly expressed in the liver and intestine and has been directly linked 
to the transcription of genes involved in the clearance of both xenobiotics (9-11), and endogenous 
toxins such as bilirubin (12). These target genes include select P450 family monooxygenases, 
phase II conjugating enzymes and xenobiotic transporters. Therefore, CAR serves as a master 
regulator of xenobiotic clearance and its activation can be considered a form of chemical 
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immunity. Within the nucleus, CAR binds to RXR and forms a functional heterodimer that 
recognizes its specific target genes. Additionally, the transcriptional activity of CAR is induced 
simply by association with RXR and with no apparent need for a CAR ligand (13-15).  Although 
ligand is not required for activation, constitutive CAR activity is mediated through the same 
conserved functional domains as those utilized by ligand-activated receptors; thus the CAR:RXR 
heterodimer recruits coactivator proteins through the AF2 transactivation domain (16,17). 
Transactivation levels mediated by CAR:RXR can be augmented by agonist ligands such as 1,4-
bis[2-(3,5-dichloropyridyloxy)] benzene (tcp) (18) and 6-(4-cholorophenyl)imidazo[2,1-
b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO) (19), which are selective 
for mouse and human CAR, respectively, while 9-cis retinoic acid (9c) can function as an RXR 
agonist (20).  In both cases, these agonists enhance constitutive activity by stabilizing the 
constitutive AF2-coactivator interaction. Additionally, transactivation by the CAR:RXR 
heterodimer can be potentiated by the RXR agonist, 9c (Figure 1A). 9c binds the ligand binding 
pocket of RXR and evokes the canonical NR conformational changes that result in direct 
interactions with coactivators. The SRC coactivator proteins function to recruit the cellular 
transcriptional machinery to activated NRs (21,22). SRCs also play an essential role as histone 
acetyltransferases to acetylate histone proteins and consequently enhance transcriptional activity 
(23). Thus, there is a direct link between agonist ligand binding, coactivator recruitment and the 
transcription of downstream genes. 
The activity of permissive NR heterodimers such as CAR:RXR that is potentiated by 
ligands to both CAR and RXR raises interesting questions about the precise structural assembly 
of nuclear factors that promote such transactivation. In this study, we propose that with permissive 
NR heterodimers represented by CAR:RXR, the levels of coactivator recruitment are proportional 
to the liganded state of the heterodimer. Thus, CAR(tcp):RXR/SRC1 is a 1:1 NR:coactivator 
complex while CAR(tcp):RXR(9c)/SRC1 exists in 1:2 binding stoichiometry. Moreover, these 
levels of coactivator recruitment are proportional to transcriptional activity (Figure 1A). These 
data further suggest that in this subset of NR heterodimers RXR performs a substantial role in 
regulating transcriptional responses within the cell. Because of the polarity of the LXRE 
DNA/CAR:RXR complex used in the transactivation assays (Experimental Procedures), CAR 
occupies the 3’ half-site, directly upstream from the luciferase gene.  Thus, a major role of the 
coactivator molecule bound to CAR is to recruit the transcriptional machinery needed for 
luciferase production.   
 
 
EXPERIMENTAL PROCEDURES 
Protein Expression and Purification 
CAR:RXR was purified as described earlier (24,25). Briefly, the murine CAR LBD (residues 
117−358) was subcloned into the pET15b vector with an N-terminal hexahistidine tag from mCAR 
cDNA kindly provided by Dr. Barry M. Forman. The human RXRα LBD (residues 225−462) was 
subcloned into the pACYC184 vector was a kind gift from Dr. Bruce Wisely (Glaxo Smith-Kline, 
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Inc.). Residues 617-769 of SRC1 (Accession no. Q15788) encompassing three nuclear receptor 
interacting motifs (RIDs) were subcloned into the pET-SUMO vector. CAR:RXR and SRC1 were 
separately isolated by affinity chromatography column using Ni-NTA resin (Qiagen Inc.) To 
prepare various CAR:RXR/SRC complexes, CAR:RXR and SRC(RID 1-3) were mixed in a 1:2 
molar ratio, after the addition of ligands, and loaded onto an S200 Superdex 16/60 column for 
purification of the resulting complexes (Figure E1). Fractions corresponding to the complexes 
were pooled, measured by Bradford Assay, and concentrated for further analysis. 
 
Analytical Ultracentrifugation  
Aliquots of CAR:RXR and SRC RID 1-3 were thawed and mixed in various ratios (1:3, 1:1, 3:1), 
incubated briefly with ligands, and analyzed on a Beckman XL ultracentrifuge. Both sedimentation 
velocity and sedimentation equilibrium experiments were performed. Sedimentation equilibrium 
was performed at 8-10ºC and 3 rotor speeds, while sedimentation velocity was run at 20ºC and 
55,000rpm. Data was analyzed using SEDFIT and SEDPHAT (26). We calculate the parameters, 
f/f0, frictional ratio; sw(20,w), sedimentation coefficient under standard conditions; and rmsd 
which reports the quality fit of the solutions of the Lamm equations (26) to the data. 
 
Small-angle X-ray Scattering  
Measurements were recorded at several beamlines: SIBLYS at Laurence Berkeley National 
Laboratory, DND-CAT at Argonne National Laboratory, and MACCHESS at Cornell. Data was 
analyzed using the ATSAS software package (27) and ScÅtter. 3D model building was performed 
using DAMMIN and MONSA (28) and visualized using Chimera. Kratky plots were calculated 
for shape analysis (29,30). The theoretical values for spherical objects in the Vc-based Kratky plot 
attain an ordinate maxima of 0.82, and for non-flexible scattering particles, 𝑞2 ∗ 𝑉𝑐 = √3, where q 
is the scattering vector (Å) and Vc is defined by the correlation length of the scattering particle as 
the ratio of the zero angle scattering intensity, I(0), to its total scattered intensity (30). 
 
Reporter gene assays  
These assays were performed as reported earlier (31). Briefly, CV-1 cells were maintained in 
DMEM/F-12 media containing 10% fetal bovine serum and 1000 U/ml penicillin and 1 mg/ml 
streptomycin. Immediately prior to the assay, the media was changed to DMEM/F-12 with 10% 
charcoal-dextran treated FBS and no antibiotics. Lipofectamine® (Invitrogen) was used to transfect 
cells with 50 ng/well pCMX mCAR, 40ng/well pCMX-Gal4-RXR, 100 ng/well pCMV-TK-luc 
containing three copies of the liver X receptor response element (LXRE) and 10 ng/well of pRL 
CMV expressing renilla luciferase as an internal control. The cells were dispensed on 24-well 
plates and ligands were added 24 hours post transfection. The ligand concentrations used were 
-cis retinoic acid. After 48 hours, cells were lysed. Activity was 
determined using the dual luciferase assay kit (Promega Inc.) following the manufacturer’s 
instructions. The reported results are the average from three separate experiments.  
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Gal4-DBD assays: The E456K mutation was made on pCMX-Gal4DBD-hRXRLBD (gift from 
Prof. Barry Forman). Transfection and assay was performed as described above with full-length 
CAR and four copies of a Gal4 binding site (pUC8-MH100x4-TK-Luc). 
 
 
RESULTS 
CAR(tcp):RXR(9c)/SRC1 Assembles as a 1:2 Heterodimer:Coactivator Complex 
To develop an understanding of how the transcriptionally active CAR:RXR assembles with 
coactivators, we prepared CAR:RXR LBD and SRC1(RID1-3) in E. coli and isolated multiple 
complexes of CAR:RXR/SRC1 (Supplementary Figure 1). Since CAR:RXR can also bind SRC1 
in the absence of agonist, for the study here we isolated the complexes CAR:RXR/SRC1, 
CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 representing the unliganded, singly-
liganded and doubly-liganded CAR:RXR complexes, respectively.  SRC1(RID1-3) used in these 
studies comprises amino acids 617-769, and encompasses the three nuclear receptor interacting 
domains (RIDs) (Supplementary Figure 1A). Also, SRC1(RID1-3) has previously been shown to 
interact in a ligand-dependent manner with CAR:RXR (15,25). Using small-angle X-ray scattering 
(SAXS), we have determined the global molecular assembly and structural properties of the 
CAR:RXR/SRC1, CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 complexes (Figure 1 and 
Supplementary Table 1). For comparisons, we also measured scattering from CAR(tcp):RXR(9c) 
and SRC1 alone and the shapes of the scattering curves are distinct and typical of their molecular 
size and flexibility. Therefore, the scattering curve of CAR:RXR heterodimer alone is 
characteristic of folded protein, while the scattering curve of SRC alone is representative of 
disordered proteins (Figure 1B). We applied Kratky analyses (29) and shape comparisons to 
identify any noticeable difference in compactness between CAR(tcp):RXR/SRC1 and 
CAR(tcp):RXR(9c)/SRC1. From these analyses we could conclude that the 
CAR(tcp):RXR(9c)/SRC1 complex is more elongated and shows greater flexibility than 
CAR(tcp):RXR/SRC1, which  suggests the presence of a second SRC1 molecule within the 
CAR(tcp):RXR(9c)/SRC1 particle. We also compare the I(0)-scaled and Vc-based Kratky 
scattering curves which emphasize differences in size and geometry of the scattering particles 
(Materials and Methods) (30). In the I(0)-normalized graphical plot, we compare the linearity and 
negative slope of the scaled intensity versus scattering angle for the complexes (Figure 1B). The 
I(0)-normalized  scattering plot of CAR(tcp):RXR(9c)/SRC1 complex is more linear with a 
sharper slope than the corresponding plots of either CAR(tcp):RXR/SRC1 or CAR:RXR/SRC1 
complexes. This clearly suggests that CAR(tcp):RXR(9c)/SRC1 is a relatively more extended 
molecule of higher molecular weight than the unliganded and singly-liganded complexes. From 
the the Vc-Kratky plot using experimental SAXS data we are able to infer that CAR:RXR alone is 
mostly spherical with no apparent flexibility, while free SRC1 shows a hyperbolic plateau that is 
indicative of a highly flexible structure and with higher surface area-to-volume ratio (Figure 1C). 
When comparing the heterodimer:coactivator complexes we note that there is a decrease in peak 
height between CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 which further indicates that 
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CAR(tcp):RXR(9c)/SRC1 is relatively extended particle (Figure 1C and Figure E1E). Overall, the 
observed scattering pattern is consistent with the presence of a second SRC molecule in the 
CAR(tcp):RXR(9c)/SRC complex. Furthermore, we note from a comparison of molecular 
envelopes of free and bound SRC1 that this molecule adopts a relatively more compact structure 
upon binding CAR:RXR, a feature that has been observed  previously in the RAR:RXR/SRC1 
complex (8). 
To visualize the assembly of these complexes we generated molecular envelopes of 
CAR:RXR/SRC1, CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 (Figure 1D, E & F). The 
molecular shapes of CAR:RXR/SRC1 and CAR(tcp):RXR/SRC1 are of an elongated species and 
are nearly identical at SAXS resolution (Figure 1E). The molecular shape of the 
CAR(tcp):RXR(9c)/SRC1 complex is also elongated and is approximately 1.4-fold larger than the 
CAR:RXR/SRC1 and CAR(tcp):RXR/SRC1 complexes (Figure 1E & F and Supplementary 
Figure 1E). To depict the assembly of each complex, the molecular envelopes of the heterodimer 
and coactivator were superimposed upon the envelope of each CAR:RXR/SRC1 complex. Both 
manual and automated fitting (see Material and Methods) suggest that both the CAR:RXR/SRC1, 
CAR(tcp):RXR/SRC1 envelopes can encompass the CAR:RXR heterodimer bound to a single 
SRC1 molecule (Figure 1E). On the other hand, the molecular shape of CAR(tcp):RXR(9c)/SRC1 
readily corresponds to a single CAR:RXR heterodimer that is bound to two SRC1(RID1-3) 
molecules (Figure 1F and Supplementary Figure 2). Thus, these SAXS analyses suggest molecular 
complexes of stoichiometries of 1:1 heterodimer:coactivator for the singly-liganded 
CAR(tcp):RXR/SRC1 and 1:2 heterodimer:coactivator for and CAR(tcp):RXR(9c)/SRC 
complexes.  
 
Analytical Ultracentrifugation for Size Determination. To establish if the shapes of 
CAR:RXR/SRC1, CAR(tcp):RXR/SRC1 and CAR(tcp):RXR(9c)/SRC1 correspond to their 
relative sizes, these complexes were independently analyzed through sedimentation velocity and 
equilibrium studies by analytical ultracentrifugation (AUC). The sedimentation velocity data 
consistently shows a species of higher sedimentation coefficient with CAR(tcp):RXR(9c)/SRC1 
than CAR(tcp):RXR/SRC1 (Figure 2A and Table 1). From sedimentation equilibrium analyses we 
confirmed the molecular weights of these species to be 84.0 kDa (CAR:RXR/SRC1 and 
CAR(tcp):RXR/SRC1) which corresponds to the size of one CAR:RXR heterodimer (55kDa) 
bound to a single SRC1 (30kDa) and 113.0 kDa for the CAR(tcp):RXR(9c)/SRC1 complex, which 
corresponds to one CAR:RXR heterodimer bound to two SRC1 molecules (Figure 2A and 
Supplementary Figure 3). The equilibrium data therefore suggests a strong preference for 2:1 
complex formation in the doubly-liganded state. Taken together, the ultracentrifugation data 
confirm that the molecular envelopes determined by SAXS correspond to the molecular weights 
of these complexes as determined by AUC. Therefore, we hypothesize that transactivation by 
CAR(tcp):RXR(9c)/SRC1 is relies on coactivator binding to both CAR and RXR.  
 
Transactivation by CAR:RXRE456K is Distorted from the Native CAR:RXR Complex  
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There are multiple factors within the cell that function to regulate transactivation by NRs (32,33). 
Of these factors, the SRC family of coactivator proteins are recruited specifically to the agonist-
bound conformation of the NR LBD (34). In this agonist-bound conformation the AF2 domain is 
realigned along the receptor surface, and in doing so creates a new interface that can bind SRC 
proteins (35). The amino acid E456 is within the AF2 domain of RXR and interacts with SRC1 
(16). To better understand the role of the RXR coactivator binding site within CAR:RXR, we 
compare the transactivation of CAR:RXRE456K with the native protein complex in a cell-based 
reporter system. This E→K amino acid substitution has previously been shown to disrupt SRC1 
recruitment by RXR (36). When tested in CV1 cells, we notice that the transcriptional response of 
CAR:RXR and CAR:RXRE456K to tcp (relative to no exogenous ligand) is similar with no 
noticeable allosteric effects of the RXRE456K mutation on CAR. However, transactivational levels 
in response to exogenously applied 9c alone (Figure 2B) and to the combination of 9c+tcp by the 
native CAR:RXR and mutant CAR:RXRE456K receptor complexes are markedly different 
(Supplementary Figure 4). The measurements of SAXS and AUC above propose a distinct role for 
RXR within the CAR:RXR complex. Together, these results suggest that in CAR:RXR the SRC-
binding site within RXR is essential for the heterodimer to achieve maximum transcriptional 
activity. Thus, relative to other NR heterodimers such as RAR:RXR and VDR:RXR (8,37), RXR 
can undertake a more significant role in transactivation by CAR:RXR. 
Biophysical and Structural Characterization of Nuclear Hormone Receptors 34 
 
 
 
 
Figure 1. Activity and assembly of CAR:RXR. (A). Transactivation of CAR:RXR measured in CV-1 cells on 3 
copies of LXRE.  (B) Scattering curve normalized to I(0) to show differences in size and deviation from globular 
shape. Blue, SRC1; cyan, CAR:RXR; Orange, CAR:RXR/SRC1, purple, CAR(tcp):RXR/SRC1; green, 
CAR(tcp):RXR(9c)/SRC1. (C) Vc based Kratky plot for visualization of flexibility and surface area-to-volume ratio. 
Molecular shapes of the complexes are generated by MONSA, while the individual heterodimer and coactivator 
envelopes are generated by DAMMIN.  (D) Top, molecular shape of free SRC1(RID1-3); bottom, molecular shape of 
CAR(tcp):RXR(9c). (E) & (F) Molecular shapes of CAR(tcp):RXR/SRC and CAR(tcp):RXR(9c)/SRC (light grey), 
respectively.  Superimposed on this is the SRC (dark grey spheres) envelope from (D) and the 
CAR:RXR/SRC(peptide, green) structure (PDB ID:1XLS). Molecular envelopes are produced by DAMMIN from 
SAXS data. 
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Figure 2. Activity of CAR and SRC1 mutants. (A). Sedimentation coefficients from sedimentation velocity 
experiments using AUC. Molecular weights shown above each peak are in kDa (See also Table 1 and Figure S2). (B). 
Transactivation by CAR:Gal4 DBD-RXR LBD and CAR:Gal4 DBD-RXRE456K LBD measured in CV-1 cells on four 
copies of a Gal4 binding site (mh100x4-tk-luc) response element. C. Models of the NR transactivation complexes. 
Top, CAR:RXR/SRC1, CAR(tcp):RXR/SRC1. Bottom, CAR(tcp):RXR(9c)/SRC1. 
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Molecular Species f/fo sw(20,w) rmsd 
CAR:RXR 1.28 4.12 0.005 
SRC1 1.5 2.1 0.007 
CAR:RXR/SRC 1.46 2.27, 4.7 0.007 
CAR(tcp):RXR/SRC 1.46 2.4, 4.7 0.006 
CAR:RXR(9c)/SRC 1.5 2.48, 5.69 0.006 
CAR(tcp):RXR(9c)/SRC 1.5 2.27, 5.6 0.009 
Table 1: AUC velocity data. f/f0, frictional ratio; sw(20,w), sedimentation coefficient under standard conditions; rmsd 
reports the quality fit to the data. A higher sedimentation coefficient for 9c and tcp+9c complexes indicates a larger 
species, while a slightly higher frictional coefficient indicates a more extended structure. 
 
DISCUSSION 
Nuclear receptors are a superfamily of structurally and functionally conserved proteins that 
have evolved to regulate transcription in response to small-molecule ligands through multiprotein 
assemblies. Hormonal agonist molecules evoke the correct structural changes within NRs to 
interact directly with coactivators, such as SRC1. Normal transactivation is dependent on the 
precise assembly of the component molecules. However, there is only a superficial mechanistic 
understanding of how this multiprotein assembly takes place, how it can be modulated and how it 
relates to transactivation. The study here illustrates the role of the agonist ligand in defining the 
molecular assembly of the NR:coactivator complex (Figure 2C).  
Both, CAR and RXR in the CAR:RXR heterodimer can independently bind their respective 
agonists (24). Also, crystallographic studies have shown that CAR(agonist):RXR(agonist) can 
bind two 13-mer LXXLL coactivator-derived peptides through binding sites on both CAR and 
RXR (16,17). This structural assembly has also been observed in other permissive NR 
heterodimers such as LXR:RXR (38) and (39). It is now clear from our data that 
these LXXLL motifs that are bound to permissive NR heterodimers are derived from two 
independent SRC1 molecules, although the intact SRC1 molecule has three distinct LXXLL-
containing RIDs (40).   
This agonist-mediated heterodimer:coactivator stoichiometry has important mechanistic 
implications for transactivation and in pharmacology. First, among the several functions ascribed 
to SRCs are the recruitment of the cellular transcriptional machinery to activated NRs (21,22,41) 
and as histone acetyltransferases (23). The polarity of heterodimers such as CAR:RXR on the 
direct repeat response element  places CAR towards the 3’ end of the promoter (42-44). Therefore, 
the most likely function of the coactivator molecule bound directly to CAR is to assemble the 
transcriptional machinery through interactions with p300/CBP (22). The addition of 9c to 
permissive NR heterodimers allows for the recruitment of a second SRC coactivator molecule 
directly to RXR on the 5’ end of the promoter. From this location, the second SRC can function 
as and recruit other histone acetyltransferases thereby enhancing transactivational levels, as 
observed with the progesterone and glucocorticoid receptors (45) (Figure 2C). Second, this 
mechanism of transactivation is a distinct alternative to that proposed for the RAR:RXR 
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heterodimer (8,37,46). In RAR:RXR, a single coactivator molecule is recruited directly to RAR 
upon activation by agonist in a conformation similar to CAR(tcp):RXR/SRC. However, the 
recruitment of a second coactivator to RAR(agonist):RXR(agonist) is restricted through long-
range, agonist-induced conformational changes that disrupt the RXR coactivator-binding site (47). 
Third, targeting coactivators for therapy is of growing interest (48,49), thus requiring a detailed 
knowledge of such binding events. These coactivators display different binding specificities for 
the receptors both independently (50) and within the heterodimer (15), thus, it is likely that the 
specific interactions between each SRC1 molecule and the two binding sites on CAR:RXR are 
distinct. The activation of CAR:RXR is not always beneficial as hepatic metabolism can convert 
certain therapeutic drugs to potent toxins.  For instance, CAR:RXR-mediated metabolism of 
acetaminophen results in a reactive quinone metabolite (N-acetyl-p-benzoquinone imine). This 
metabolic by-product promotes acute liver failure by binding to cellular macromolecules and by 
generating reactive oxygen species (10,51). The hepatotoxic effects of cocaine are also mediated 
via a CAR:RXR–dependent pathway (9).  Thus, the activity of CAR:RXR can have either 
protective or deleterious consequences to the organism depending on the particular chemical 
challenges faced by it.  Also, the discoveries of endogenous RXR ligands such as polyunsaturated 
fatty acids (52-54) increase the likelihood of two agonists binding the CAR:RXR heterodimer at 
once. Thus, this novel assembly has important implications for the design of small molecules 
directed at regulating transactivation by modulating the formation and composition of the NR-
coactivator assembly.
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